TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26529632

Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment (1 mg/kg six times per week or 2 mg/kg thrice weekly)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment
Number of subjects: 37
Study: 26530031

Group type: EXPERIMENTAL
Intervention: Standard homework
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simplified (picture-based) homework
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electronic reminders
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simplified homework
Number of subjects: 12
Study: 26530268

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1299

Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1299
Study: 26531748

Group type: EXPERIMENTAL
Intervention: Standard primary treatment according to the stage of disease
Number of subjects: 700
Study: 26535053

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure for 10 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham group (light pressure on non-acupoints for 10 days)
Number of subjects: 78
Study: 26535123

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 580
Study: 26535126

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Naloxegol (both doses)
Number of subjects: 240
Study: 26535134

Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 4 weeks (120/Q4W)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Tabalumab 90 mg every 2 weeks (90/Q2W)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study: 26535135

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg plus Methotrexate (MTX) for 52 weeks
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Responders (DAS28 ≤3.2) at week 13
Number of subjects: 196

Group type: COMPARATOR
Intervention: Non-responders (DAS28 >3.2) at week 13
Number of subjects: 196
Study: 26535146

Group type: EXPERIMENTAL
Intervention: Delayed-release (DR) prednisone 5 mg once daily for 12 weeks
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 350
Study: 26535512

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus Rituximab
Number of subjects: 38
Study: 26536156

Group type: EXPERIMENTAL
Intervention: TranQuill Sling Snoreplasty (TSS)
Number of subjects: 20
Study: 26536198

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1
Study: 26536893

Group type: EXPERIMENTAL
Intervention: Triheptanoin treatment
Number of subjects: 8
Study: 26537529

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day
Number of subjects: 286
Study: 26537623

Group type: EXPERIMENTAL
Intervention: Romiplostim (starting dose of 1 μg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Romiplostim (after discontinuation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Romiplostim (during treatment)
Number of subjects: 24
Study: 26537851

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow derived MSCs, 1.5 × 10(6) per kg body weight, administered intravenously at 25 and 26 weeks after transplantation.
Number of subjects: 10
Study: 26538309

Group type: EXPERIMENTAL
Intervention: In-line microfilters
Number of subjects: 504

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 504
Study: 26538477

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (BWLI)
Number of subjects: 470
Study: 26539981

Group type: EXPERIMENTAL
Intervention: Rituximab (1 g at D0, D15, and M6)
Number of subjects: 12
Study: 26540234

Group type: EXPERIMENTAL
Intervention: Increased BSM mass in nonsevere asthma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High BSM
Number of subjects: 34
Study: 26540612

Group type: EXPERIMENTAL
Intervention: Sleep-Disordered Breathing (SDB) in patients with CMS
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Presence of Patent Foramen Ovale (PFO) in subjects with SDB
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation of AHI with systemic blood pressure
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation of AHI with pulmonary artery pressure
Number of subjects: 23
Study: 26541344

Group type: EXPERIMENTAL
Intervention: Caloric intake quartile 2 (3.0 ± 0.7 kcal/kg/day)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Caloric intake quartile 1 (0.5 ± 0.6 kcal/kg/day)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Caloric intake quartiles 1 and 2
Number of subjects: 1004
Study: 26541392

Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM)
Number of subjects: 17
Study: 26541511

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg, up to four cycles, administered in 3 week intervals)
Number of subjects: 103
Study: 26541586

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (IMMU-132)
Number of subjects: 6
Study: 26542025

Group type: EXPERIMENTAL
Intervention: Shared reporting (patients self-reported toxicities and performance status viewed by clinicians)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-shared reporting (patients self-reported toxicities but reports not shared with clinicians)
Number of subjects: 44
Study: 26542280

Group type: EXPERIMENTAL
Intervention: Osilodrostat (LCI699)
Number of subjects: 19
Study: 26542378

Group type: EXPERIMENTAL
Intervention: ONO/GS-4059 (20 mg to 600 mg once daily, with twice-daily regimens of 240 mg and 300 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ONO/GS-4059
Number of subjects: 90
Study: 26542493

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Provider surveys
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Chart abstraction and core laboratory lipid levels
Number of subjects: 7500
Study: 26542691

Group type: EXPERIMENTAL
Intervention: Dynamic computed tomographic angiography (CTA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single-phase CTA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dynamic CTA
Number of subjects: 70
Study: 26543510

Group type: EXPERIMENTAL
Intervention: 30 mg daily oral pioglitazone for 28 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26543765

Group type: EXPERIMENTAL
Intervention: Schedule A: 3-weekly epirubicin (90 mg/m2) and docetaxel (75 mg/m2) chemotherapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Schedule B: 2-weekly epirubicin (60 mg/m2) and docetaxel (60 mg/m2) chemotherapy
Number of subjects: 93
Study: 26543906

Group type: EXPERIMENTAL
Intervention: Smartphone (iPhone 4S)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lawson SMART Record (LSR)
Number of subjects: 400
Study: 26544192

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 40
Study: 26544668

Group type: EXPERIMENTAL
Intervention: Healthy youth
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Anxious youth
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Healthy adults
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Anxious adults
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Emotional tasks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Nonemotional tasks
Number of subjects: 111
Study: 26544725

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (161 participants)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (67 participants)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Total cohort (242 participants)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Participants with type 2 diabetes at baseline
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Participants with abnormal kidney function at baseline
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Participants with prediabetes at baseline
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Participants with elevated blood pressure at baseline
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Participants with dyslipidemia at baseline
Number of subjects: 242
Study: 26544959

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (assessed by Nugent score)
Number of subjects: 728
Study: 26545441

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 200 mg 1-h i.v. infusion post-haemodialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ceftaroline fosamil 600 mg 1-h i.v. infusion in healthy volunteers
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 200 mg 1-h i.v. infusion pre-haemodialysis
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 200 mg 1-h i.v. infusion (pre- and post-haemodialysis)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (pre- and post-haemodialysis)
Number of subjects: 8
Study: 26545911

Group type: EXPERIMENTAL
Intervention: Thrombophilic SNPs (factor V Leiden, H1299R, prothrombin G20210A, factor XIII V34L, β-fibrinogen -455G → A, plasminogen activator inhibitor-1 4G/5G, human platelet antigen-1 a/b9L33P, methylenetetrahydrofolate reductase C677T and A1298C)
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Cumulative number of thrombophilic mutations
Number of subjects: 1717
Study: 26546060

Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Age, albumin, presence of arteriovenous fistula calcification
Number of subjects: 350

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 350
Study: 26546259

Group type: EXPERIMENTAL
Intervention: 20μg dose of RVEc™
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50μg dose of RVEc™
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100μg dose of RVEc™
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Booster dose of RVEc™ (20-21 months after initial dose)
Number of subjects: 30
Study: 26547188

Group type: EXPERIMENTAL
Intervention: Helical IMRT of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated boost to the prostate (76.5 Gy) in 34 fractions, following at least two months of antihormonal treatment before radiotherapy continuing for at least 2 years.
Number of subjects: 40
Study: 26547226

Group type: EXPERIMENTAL
Intervention: Energy drink consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or no energy drink)
Number of subjects: 0
Study: 26547914

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches (5-20 μg/h and 35-70 μg/h)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches
Number of subjects: 465
Study: 26551877

Group type: EXPERIMENTAL
Intervention: Transcatheter pacemaker
Number of subjects: 725
Study: 26552042

Group type: EXPERIMENTAL
Intervention: WEB treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: WEB treatment with antiplatelet agents
Number of subjects: 113
Study: 26552419

Group type: EXPERIMENTAL
Intervention: Combined MSI typing, MLH1 methylation analysis, and immunohistochemistry (IHC)
Number of subjects: 1002
Study: 26552564

Group type: EXPERIMENTAL
Intervention: Cardiac-based seizure detection algorithm (CBSDA) triggering Vagus Nerve Stimulation (VNS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Number of subjects: 31
Study: 26553234

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26553695

Group type: EXPERIMENTAL
Intervention: RUNX2 gene expression in calcified valves
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: CACNA1C gene expression in calcified valves
Number of subjects: 474

Group type: COMPARATOR
Intervention: Genome-wide association studies (GWAS) results
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Association of RUNX2 with AS
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Association of CACNA1C with AS
Number of subjects: 474
Study: 26553837

Group type: EXPERIMENTAL
Intervention: Recruitment procedures and acceptability of participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline biophysical, genetic, socioeconomic, behavioural and psychological assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnancy and postpregnancy assessments
Number of subjects: 0
Study: 26554383

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay on induced sputum samples
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay on gastric lavage samples
Number of subjects: 1020

Group type: COMPARATOR
Intervention: MGIT culture on induced sputum samples
Number of subjects: 1020

Group type: COMPARATOR
Intervention: MGIT culture on gastric lavage samples
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Combined results from Xpert MTB/RIF assay or MGIT culture
Number of subjects: 1020
Study: 26554629

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Nonwhite race
Number of subjects: 1915
Study: 26554651

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate and gemcitabine (1.0 mg/m² eribulin and 1000 mg/m² gemcitabine on days 1 and 8 of a 28-day cycle)
Number of subjects: 45
Study: 26554876

Group type: EXPERIMENTAL
Intervention: Tanezumab treatment
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Higher doses of tanezumab
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tanezumab administered with nonsteroidal antiinflammatory drugs
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Preexisting subchondral insufficiency fractures
Number of subjects: 249
Study: 26555635

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Increasing non-fasting glucose levels
Number of subjects: 194
Study: 26555692

Group type: EXPERIMENTAL
Intervention: Consideration of undiagnosed neurological conditions in male LUTS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging (MRI scan)
Number of subjects: 0
Study: 26555948

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Risk factor assessment
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 167
Study: 26556476

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (nCR)
Number of subjects: 642

Group type: COMPARATOR
Intervention: No neoadjuvant chemoradiation (no nCR)
Number of subjects: 642
Study: 26556899

Group type: EXPERIMENTAL
Intervention: Re-intubation within 72 hours after extubation
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen level >8.2 mmol/L
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Hemoglobin level <75 g/L
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Muscle strength ≤3
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Presence of all 3 risk factors (blood urea nitrogen >8.2 mmol/L, hemoglobin <75 g/L, muscle strength ≤3)
Number of subjects: 764
Study: 26557215

Group type: EXPERIMENTAL
Intervention: Twice-daily regimen of cleanser (7.8% 1-lactic acid, 2% salicylic acid) and anti-aging serum (0.1% alpha hydroxy acids-retinoids, 6.5% 1-lactic acid) with concurrent use of sun protection factor 50+ sunscreen as needed
Number of subjects: 25
Study: 26557787

Group type: EXPERIMENTAL
Intervention: Stimulus control therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random assignment to treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preference allocation to chosen treatment
Number of subjects: 0
Study: 26558819

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 325
Study: 26558829

Group type: EXPERIMENTAL
Intervention: School-based violence prevention intervention
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Implementation of sensitisation and consent procedures
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Referral algorithm developed in conjunction with local services
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Mandatory reporting of children's disclosures to local services
Number of subjects: 3700
Study: 26559139

Group type: EXPERIMENTAL
Intervention: Interferon β-1a 44 μg subcutaneously three times a week (SC tiw)
Number of subjects: 23
Study: 26559386

Group type: EXPERIMENTAL
Intervention: Mechanical valves
Number of subjects: 4545

Group type: COMPARATOR
Intervention: Bioprosthetic valves
Number of subjects: 4545
Study: 26559401

Group type: EXPERIMENTAL
Intervention: Storage-aged red blood cell transfusions
Number of subjects: 0
Study: 26559535

Group type: EXPERIMENTAL
Intervention: Stem cell-based tissue-engineered tracheas
Number of subjects: 3
Study: 26559634

Group type: EXPERIMENTAL
Intervention: Cervical inversion technique
Number of subjects: 40
Study: 26559790

Group type: EXPERIMENTAL
Intervention: Combined treatment with escitalopram (mean daily dose 18.62 mg, SD 5.15) and memantine (mean daily dose 13.62 mg, SD 6.67)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined treatment with escitalopram and memantine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined treatment with escitalopram and memantine in the amnestic mild cognitive impairment subsample (n = 22)
Number of subjects: 35
Study: 26560486

Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed (500 mg/m2 iv on Day 1, nintedanib 100 mg bid escalating to 200 mg bid on days 2-21)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed
Number of subjects: 18
Study: 26561620

Group type: EXPERIMENTAL
Intervention: Lowest physical activity group (15.7 ± 9.9 min MVPA/d, 6062 ± 1778 steps/d)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Middle activity group
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Most-active group (174.5 ± 60.5 min MVPA/d, 10260 ± 3087 steps/d)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Lowest physical activity group
Number of subjects: 421
Study: 26561627

Group type: EXPERIMENTAL
Intervention: High manganese exposure (parenteral nutrition)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Low manganese exposure (parenteral nutrition)
Number of subjects: 73
Study: 26561629

Group type: EXPERIMENTAL
Intervention: ¹³C-lycopene (10.2 mg)
Number of subjects: 8
Study: 26561916

Group type: EXPERIMENTAL
Intervention: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as initial hemostasis in group A (5 mL)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as rescue therapy in group B (5 mL)
Number of subjects: 37
Study: 26562321

Group type: EXPERIMENTAL
Intervention: Vaccinated individuals
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Vaccinated patients with A/H3N2 infection
Number of subjects: 155

Group type: COMPARATOR
Intervention: Unvaccinated participants with A/H1N1 infection
Number of subjects: 155
Study: 26562532

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (vancomycin 500 mg, gentamycin 40 mg, meropenem 500 mg once-daily for 4 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (vancomycin, gentamycin, meropenem)
Number of subjects: 12
Study: 26562836

Group type: EXPERIMENTAL
Intervention: Synthetic ACTH (intramuscular injections, max 1 mg twice a week for 9 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclophosphamide and steroids (historical control)
Number of subjects: 20
Study: 26563220

Group type: EXPERIMENTAL
Intervention: Integrated HIV counseling and family planning services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stand-alone services (comparison group)
Number of subjects: 0
Study: 26563229

Group type: EXPERIMENTAL
Intervention: Treatment for generalized anxiety disorder, panic disorder, social anxiety disorder (SAD), or post-traumatic stress disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for social anxiety disorder (SAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comorbid depression and low socioeconomic status
Number of subjects: 0
Study: 26563323

Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024% instilled once daily (QD) for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024% instilled QD for 14 days
Number of subjects: 24
Study: 26563363

Group type: EXPERIMENTAL
Intervention: BAK-free travoprost 0.004 % (Travatan® preserved with POLYQUAD®) for 12 weeks
Number of subjects: 191
Study: 26564730

Group type: EXPERIMENTAL
Intervention: Midfoot Fusion Bolt (MFB, Synthes GmbH)
Number of subjects: 47
Study: 26565008

Group type: EXPERIMENTAL
Intervention: RBX2660 (microbiota suspension) administered via enema
Number of subjects: 40
Study: 26565381

Group type: EXPERIMENTAL
Intervention: Entrectinib (RXDX-101)
Number of subjects: 1
Study: 26565813

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metabolic products of the mevalonate pathway (mevalonate, farnesyl pyrophosphate, geranylgeranyl pyrophosphate)
Number of subjects: 0
Study: 26565981

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 22
Study: 26566161

Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg twice daily with a background regimen (boosted protease inhibitor plus nucleoside/nucleotide reverse transcriptase inhibitors, optional enfuvirtide/raltegravir)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg twice daily
Number of subjects: 101
Study: 26566324

Group type: EXPERIMENTAL
Intervention: Large head (Magnum) prostheses
Number of subjects: 164

Group type: COMPARATOR
Intervention: Conventional femoral head prostheses
Number of subjects: 164
Study: 26566446

Group type: EXPERIMENTAL
Intervention: Bollywood dance classes (1 hour, twice per week for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bollywood dance classes (for participants attending at least 10 of 16 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (for participants attending fewer sessions)
Number of subjects: 0